On December 22, 2023, Alaunos Therapeutics Entered Into Separation And Release Agreement With CEO Kevin Boyle In Connection With Boyle's Termination - Filing
On December 22, 2023, Alaunos Therapeutics Entered Into Separation And Release Agreement With CEO Kevin Boyle In Connection With Boyle's Termination - Filing
2023年12月22日，Alaunos Therapeutics与首席执行官凯文·博伊尔就博伊尔的解雇签订了分离和释放协议——备案
The Company and Boyle also entered into a consulting agreement, effective January 1, 2024, pursuant to which Boyle will continue providing strategic and advisory services to the company. The Consulting Agreement will continue for a period of six months.
该公司和博伊尔还签订了咨询协议，该协议自2024年1月1日起生效，根据该协议，博伊尔将继续向公司提供战略和咨询服务。咨询协议将持续六个月。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。